Middle East and Africa Hereditary Cancer Testing Market – Industry Trends and Forecast to 2029

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Middle East and Africa Hereditary Cancer Testing Market – Industry Trends and Forecast to 2029

  • Medical Devices
  • Published Report
  • Nov 2022
  • MEA
  • 350 Páginas
  • Número de tablas: 99
  • Número de figuras: 43

Middle East and Africa Hereditary Cancer Testing  Market, By Test Type (Multi Panel Set, and Single Site Genetic Test), Diagnosis Type (Biopsy, Imaging, Lab Tests), Technology (Sequencing, Polymerase Chain Reaction (PCR), Microarray), Disease Type (Hereditary Breast & Ovarian Cancer Syndrome, Cowden Syndrome, Lynch Syndrome, Hereditary Leukemia And Hematologic Malignancies Syndromes, Familial Adenomatous Polyposis (FAP), Li-Fraumeni Syndrome, Von Hippel-Lindau Disease, Multiple Endocrine Neoplasias (MEN) Syndromes), End User (Hospitals, Clinics, Laboratories, Radiology Centers, Diagnostic Centers, Others), Distribution Channel (Direct Tender, Retail Sales), Trends and Forecast to 2029.

Middle East and Africa Hereditary Cancer Testing Market Analysis and Insights

Cancer is a genetic disease caused by certain mutations in the genes that control the function of cells, particularly affecting their growth and reproduction. Inherited genetic mutations are responsible for approximately 5-10% of all cancers. Researchers have linked mutations in specific genes to more than 50 hereditary cancer syndromes that affect people through the development of certain cancers. In addition, about 5-10% of breast cancer cases are associated with genetic mutations inherited from parents. Thus, the increasing prevalence of cancer is driving the steady growth of hereditary cancers and thus, driving the growth of the hereditary cancer testing market. In addition, increased demand for non-invasive testing methods and growing demand for better quality healthcare and early diagnosis are the major opportunities for the market growth. Moreover, Ethical challenges faced during hereditary cancer testing and rising competition among market players are the key challenges for the market growth.

However, stringent cancer diagnostic regulations and the high cost associated with tests may hamper the growth of the market.

Data Bridge Market Research analyzes that the Middle East and Africa hereditary cancer testing market is expected to reach the value of USD 361.76 million by 2029, at a CAGR of 11.2% during the forecast period. This market report also covers pricing analysis, patent analysis, and technological advancements in depth.

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2019 - 2015)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

By Test Type (Multi Panel Set, and Single Site Genetic Test), Diagnosis Type (Biopsy, Imaging, Lab Tests), Technology (Sequencing, Polymerase Chain Reaction (PCR), Microarray), Disease Type (Hereditary Breast & Ovarian Cancer Syndrome, Cowden Syndrome, Lynch Syndrome, Hereditary Leukemia And Hematologic Malignancies Syndromes, Familial Adenomatous Polyposis (FAP), Li-Fraumeni Syndrome, Von Hippel-Lindau Disease, Multiple Endocrine Neoplasias (MEN) Syndromes), End User (Hospitals, Clinics, Laboratories, Radiology Centers, Diagnostic Centers, Others), Distribution Channel (Direct Tender, Retail Sales).

Countries Covered

South Africa, Saudi Arabia, UAE, Egypt, Israel, and the rest of the Middle East and Africa.

Market Players Covered

Invitae Corporation, Illumina, Inc., Natera, Inc., CENTOGENE N.V., 4baseCare, Biocartis, Fulgent Genetics, Ambry Genetics, BioReference, PerkinElmer Inc., LifeLabs, Abbott, BIO-HELIX, Cepheid, Eurofins Scientific, among others.

Middle East and Africa Hereditary Cancer Testing Market Definition

Hereditary cancer is any cancer caused by an inherited genetic mutation. Harmful variants in certain genes are associated with an increased risk of cancer. Genetic testing can estimate a person's lifetime risk of developing cancer. This can be done by looking for mutations in their genes, chromosomes, or proteins. Genetic testing is available for several types of cancer. These include breast, ovarian, colon, thyroid, prostate, pancreatic, skin cancer, sarcoma, and kidney and stomach cancer. Numerous medical studies show that 5% to 10% of common cancers are considered hereditary. Genetic tests are performed to determine whether a person carries a harmful genetic variant. These tests also help determine if a family member who has not yet had cancer has inherited the same variant as a family member known to have a cancer susceptibility alternative.

Middle East and Africa Hereditary Cancer Testing Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

  • Rising Incidence of Hereditary Cancer

Cancer arises from the uncontrolled growth of cells. Cancer is caused by harmful changes (mutations) in genetic messages (genes) that control the growth and division of cells, preventing them from doing their job effectively.

  • In hereditary cancer cases, the individual inherits a copy of the mutated growth regulatory gene from one parent and a working copy of the same gene from the other parent. The mutated gene is also called a "cancer susceptibility gene." As this cancer-susceptibility gene is inherited, it is found in every cell in the body, but a working copy of the gene keeps each cell functioning properly. However, if a mutation damages a functional copy of a gene in a cell, the cell can lose control of its growth and become cancerous. Thus, individuals who inherit a cancer gene are much more likely to develop certain cancers during their lifetime.

Thus, rising incidences of hereditary cancer increase the demand for hereditary cancer testing and may act as a driver for the growth of the Middle East and Africa hereditary cancer testing market.

  •  Increase in The Geriatric Population

Cancer can be a disease of aging patients. Across the globe, the geriatric population is increasing. The risk of hereditary cancer among geriatrics is much more. The rising geriatric population can result in better provision of the Middle East and Africa hereditary cancer testing market. It anticipated an upsurge in demand in the Middle East and Africa hereditary cancer testing market. An aging population is causing a redistribution of the demographic structure that will affect the future of health care. Undoubtedly, the risk of cancer increases exponentially with age.

Hereditary cancer, including its incidence and associated risk, using the world's largest complete family structure and medically confirmed cancer database, was approximately twice as high in the population aged 8-20 years born to affected parents or siblings of people who have no relatives. The risk of small bowel, testicular, thyroid, and bone cancers was five to eight times greater.

Thus, the increase in cancer incidences among the geriatric population is expected to be a driving factor for the growth of the Middle East and Africa hereditary cancer testing market.

Restraint

  • High Cost of Hereditary Cancer Testing

Hereditary cancer testing employs highly technologically advanced products. The development of these products involves rigorous research and development by the developing player. Thus, the procedures and product cost remains high, which proportionally increases the cost of testing. Testing kits are expensive because they are incredibly resource-intensive and involve high-paid doctors, transportation, and expensive medications.

  • In addition, testing procedures have also been used in cancer testing. However, such procedures are very expensive and may be associated with complications and worse long-term outcomes.

Thus, the high cost of cancer testing using advanced modalities and technology products may be a major restraining factor for the growth of the Middle East and Africa hereditary cancer testing market.

Opportunity

  • Strategic Initiatives by Market Players

The rise in the Middle East and Africa hereditary cancer testing market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The surge in demand for hereditary cancer treatment is significantly increasing the demand for diagnostic testing methods. The planned strategies allow the market players to align with the organization's functional activities to achieve set goals. It guides the company's discussions and decision-making in determining resource and budget requirements to accomplish objectives, thus increasing operational efficiency.

These strategic initiatives, such as product launches, agreements, and business expansion by the major market players, will boost the market growth and are expected to act as an opportunity for the Middle East and Africa hereditary cancer testing market. The strategic initiatives are expected to aid in growth and improve the company's product portfolio, ultimately leading to more revenue generation. Hence, these strategic initiatives by the market players are expected to act as an opportunity for growth in the Middle East and Africa hereditary cancer testing market.

Challenge

  • Ethical Challenges Faced During Hereditary Cancer Testing

During hereditary cancer genetic testing, one of the significant ethical hindrances is health professionals' lack of basic knowledge about genetic testing and their lack of confidence in interpreting familial disease patterns. The challenge for healthcare providers is to provide sufficient information to support patient decision making-and evidence to support the reasoning behind any suggestions they might make.

The lack of reimbursement creates economic barriers to care. The process of hereditary cancer risk assessment and counseling is time-consuming, and it is unclear how best to document and bill for this service. Oncologists are often forced to navigate a potentially uncertain reimbursement environment for genetic testing, with various reimbursement policies among third-party payers.

Genetic testing for hereditary cancer elevates ethical matters, which can't be resolved with patients or their family members. The various aspects of ethical, cultural, and religious nature should not be a barrier to the act of hereditary cancer testing. All of these are issues to be solved. Therefore, ethical challenges during hereditary cancer testing are expected to challenge the market growth.

Post-COVID-19 Impact on Middle East and Africa Hereditary Cancer Testing Market

Many industries around the world have been disadvantaged over the past 18 months. This could be due to the major disruptions that their industrial and supply chain processes are experiencing due to various precautionary measures such as shutdowns and other restrictions that the facilities around the world have been following. The same places the Middle East and Africa hereditary cancer testing market. Also, consumption demand has subsequently decreased as people now have more opportunities to exclude non-essential expenses from their budgets as most people's overall finances have been severely affected by the boom. These aforementioned factors can be expected to burden the revenue margin of the Middle East and Africa hereditary cancer testing market during the forecast period.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities and product launch and strategic partnerships to improve the technology and test results involved in the transplant diagnostics market.

Recent Developments

  • In July 2022, Helio Genomics and its business partner, Fulgent Genetics (FLGT) has announced that the American Medical Association (AMA)  issued a new Category I Current Procedural Terminology (CPT) Proprietary Laboratory Analyses code for HelioLiver and broader adoption of advanced innovative surveillance tests for liver cancer in the U.S. This has helped the company to expand their product portfolio.
  • In March 2022, Illumina, Inc. introduced the n vitro diagnostic (IVD) kit, a cancer RNA sequencer. The launch resulted in expansion of the sequencing product line, followed by post market approval. It is depicted to show a linear market growth.

Middle East and Africa Hereditary Cancer Testing Market Scope

Middle East and Africa hereditary cancer testing market is segmented into test type, diagnosis type, technology, disease type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

TEST TYPE

  • MULTI PANEL TEST
  • SINGLE SITE GENETIC TEST

On the basis of test type, the Middle East and Africa hereditary cancer testing market is segmented into multi panel test and single site genetic test.

BY DIAGNOSIS TYPE

  • BIOPSY
  • IMAGING
  • LAB TESTS

On the basis of diagnosis type, the Middle East and Africa hereditary cancer testing market is segmented into biopsy, imaging, and lab tests.

BY TECHNOLOGY

  • SEQUENCING
  • POLYMERASE CHAIN REACTION (PCR)
  • MICROARRAY

On the basis of technology, the Middle East and Africa hereditary cancer testing market is segmented into sequencing, polymerase chain reaction (PCR), and microarray.

BY DISEASE TYPE

  • HEREDITARY BREAST & OVARIAN CANCER SYNDROME
  • COWDEN SYNDROME
  • LYNCH SYNDROME
  • HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROMES
  • FAMILIAL ADENOMATOUS POLYPOSIS (FAP)
  • LI-FRAUMENI SYNDROME
  • VON HIPPEL-LINDAU DISEASE
  • MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROMES

On the basis of disease type, the Middle East and Africa hereditary cancer testing market is segmented into hereditary breast & ovarian cancer syndrome, cowden syndrome, lynch syndrome, hereditary leukemia and hematologic malignancies syndromes, familial adenomatous polyposis (FAP), li-fraumeni syndrome, vol-hippel lindau disease, multiple endocrine neoplasias (MEN) syndrome.

BY END USER

  • HOSPITALS
  • CLINICS
  • LABORATORIES
  • RADIOLOGY CENTERS 
  • DIAGNOSTIC CENTERS
  • OTHERS

On the basis of end user, the Middle East and Africa hereditary cancer testing market is segmented into hospitals, clinics, laboratories, radiology centers, diagnostic centers, and others.

BY DISTRIBUTION CHANNEL

  • DIRECT TENDER
  • RETAIL SALES

On the basis of distribution channel, the Middle East and Africa hereditary cancer testing market is segmented into direct tender, retail sales.

Middle East and Africa Hereditary Cancer Testing Market Regional Analysis/Insights

The Middle East and Africa hereditary cancer testing market is analyzed and market size information is provided by test type, diagnosis type, technology, disease type, end user, and distribution channel.

The countries covered in this market report South Africa, Saudi Arabia, UAE, Egypt, Israel, and the rest of the Middle East and Africa,

  • In 2022, South Africa is dominating due to the increasing investment for the R&D in hereditary cancer market.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of Middle East and Africa brands and their challenges faced due to large or scarce competition from local and domestic brands, and impact of sales channels are considered while providing forecast analysis of the country data.

Competitive Landscape and Middle East and Africa Hereditary Cancer Testing Market Share Analysis

Middle East and Africa hereditary cancer testing market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in R&D, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width and breath, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the Middle East and Africa hereditary cancer testing market.

Some of the major players operating in the Middle East and Africa hereditary cancer testing market are Invitae Corporation, Illumina, Inc., Natera, Inc., CENTOGENE N.V., 4baseCare, Biocartis, Fulgent Genetics, Ambry Genetics, BioReference, PerkinElmer Inc., LifeLabs, Abbott, BIO-HELIX, Cepheid, Eurofins Scientific, among others.

Research Methodology: Middle East and Africa Hereditary Cancer Testing Market

Data collection and base year analysis are done using data collection modules with large sample sizes. The market data is analyzed and estimated using market statistical and coherent models. In addition, market share analysis and key trend analysis are the major success factors in the market report. The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Middle East and Africa vs Regional, and Vendor Share Analysis. Please request analyst call in case of further inquiry.


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET END USER COVERAGE GRID

2.8 SOURCE LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: REGULATIONS

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING INCIDENCE OF HEREDITARY CANCER

6.1.2 INCREASE IN THE GERIATRIC POPULATION

6.1.3 RISING HEALTHCARE SPENDING

6.1.4 INCREASE IN AWARENESS ABOUT CANCER TESTING

6.2 RESTRAINTS

6.2.1 HIGH COST OF HEREDITARY CANCER TESTING

6.2.2 LACK OF SKILLED PROFESSIONALS

6.3 OPPORTUNITIES

6.3.1 STRATEGIC INITIATIVES BY MARKET PLAYERS

6.3.2 INCREASED DEMAND FOR NON-INVASIVE TESTING METHODS

6.3.3 GROWING DEMAND FOR BETTER QUALITY HEALTHCARE AND EARLY DIAGNOSIS

6.3.4 TECHNOLOGICAL DEVELOPMENTS IN HEREDITARY CANCER TESTING PROCEDURES

6.4 CHALLENGES

6.4.1 ETHICAL CHALLENGES FACED DURING HEREDITARY CANCER TESTING

6.4.2 RISING COMPETITION AMONG MARKET PLAYERS

7 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE

7.1 OVERVIEW

7.2 MULTI PANEL TEST

7.3 SINGLE-SITE GENETIC TEST

8 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE

8.1 OVERVIEW

8.2 BIOPSY

8.2.1 NEEDLE BIOPSIES

8.2.2 ENDOSCOPIC BIOPSIES

8.2.3 LAPAROSCOPIC, THORACOSCOPIC, AND MEDIASTINOSCOPIC BIOPSY

8.2.4 LAPAROTOMY AND THORACOTOMY

8.2.5 OTHERS

8.3 IMAGING

8.3.1 MAGNETIC RESONANCE IMAGING (MRI)

8.3.2 COMPUTED TOMOGRAPHY (CT) SCAN

8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN

8.3.4 NUCLEAR SCAN

8.3.5 ULTRASOUND

8.3.6 X-RAYS

8.4 LAB TESTS

8.4.1 BLOOD

8.4.2 URINE

8.4.3 OTHERS

9 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY

9.1 OVERVIEW

9.2 POLYMERASE CHAIN REACTION (PCR)

9.3 SEQUENCING

9.4 MICRO ARRAY

10 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE

10.1 OVERVIEW

10.2 HEREDITARY BREAST & OVARIAN CANCER SYNDROME

10.3 COWDEN SYNDROME

10.4 LYNCH SYNDROME

10.5 HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME

10.6 FAMILIAL ADENOMATOUS POLYPOSIS (FAP)

10.7 LI-FRAUMENI SYNDROME

10.8 VON HIPPEL-LINDAU DISEASE

10.9 MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME

11 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 CLINICS

11.4 DIAGNOSTIC CENTERS

11.5 RADIOLOGY CENTERS

11.6 LABORATORIES

11.7 OTHERS

12 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 DIRECT TENDER

12.3 RETAIL SALES

13 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY REGION

13.1 MIDDLE EAST AND AFRICA

13.1.1 SOUTH AFRICA

13.1.2 SAUDI ARABIA

13.1.3 U.A.E.

13.1.4 EGYPT

13.1.5 ISRAEL

13.1.6 REST OF THE MIDDLE EAST AND AFRICA

14 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST & AFRICA

15 SWOT ANALYSIS

16 COMPANY PROFILE

16.1 ABBOTT

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENTS

16.2 ILLUMINA, INC. (2021)

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 PERKINELMER INC. (2021)

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 LIFELABS GENETICS

16.4.1 COMPANY SNAPSHOT

16.4.2 COMPANY SHARE ANALYSIS

16.4.3 PRODUCT PORTFOLIO

16.4.4 RECENT DEVELOPMENTS

16.5 EUROFINS SCIENTIFIC (2021)

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENT

16.6 AMBRY GENETICS

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENTS

16.7 BIOCARTIS

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 RECENT DEVELOPMENTS

16.8 BIO-HELIX

16.8.1 COMPANY SNAPSHOT

16.8.2 PRODUCT PORTFOLIO

16.8.3 RECENT DEVELOPMENTS

16.9 BIOREFERENCE (A SUBSIDIARY OF OPKO HEALTH, INC.) (2021)

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.1 CENTOGENE N.V. (2021)

16.10.1 COMPANY SNAPSHOT

16.10.2 REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 CEPHEID

16.11.1 COMPANY SNAPSHOT

16.11.2 PRODUCT PORTFOLIO

16.11.3 RECENT DEVELOPMENT

16.12 FULGENT GENETICS

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENT

16.13 INVITAE CORPORATION

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 NATERA, INC. (2021)

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENTS

16.15 4BASECARE.

16.15.1 COMPANY SNAPSHOT

16.15.2 PRODUCT PORTFOLIO

16.15.3 RECENT DEVELOPMENTS

17 QUESTIONNAIRE

18 RELATED REPORTS

Lista de Tablas

TABLE 1 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

TABLE 2 MIDDLE EAST & AFRICA MULTI PANEL TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 MIDDLE EAST & AFRICA SINGLE-SITE GENETIC TEST IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 4 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 5 MIDDLE EAST & AFRICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 6 MIDDLE EAST & AFRICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 7 MIDDLE EAST & AFRICA IMAGING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 MIDDLE EAST & AFRICA IMAGING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 9 MIDDLE EAST & AFRICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 10 MIDDLE EAST & AFRICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 11 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 12 MIDDLE EAST & AFRICA POLYMERASE CHAIN REACTION (PCR) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 MIDDLE EAST & AFRICA SEQUENCING IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 MIDDLE EAST & AFRICA MICROARRAY IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 16 MIDDLE EAST & AFRICA HEREDITARY BREAST & OVARIAN CANCER SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 MIDDLE EAST & AFRICA COWDEN SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 18 MIDDLE EAST & AFRICA LYNCH SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 MIDDLE EAST & AFRICA HEREDITARY LEUKEMIA AND HEMATOLOGIC MALIGNANCIES SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 MIDDLE EAST & AFRICA FAMILIAL ADENOMATOUS POLYPOSIS (FAP) IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 21 MIDDLE EAST & AFRICA LI-FRAUMENI SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 22 MIDDLE EAST & AFRICA VON HIPPEL-LINDAU DISEASE IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 MIDDLE EAST & AFRICA MULTIPLE ENDOCRINE NEOPLASIAS (MEN) SYNDROME IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 25 MIDDLE EAST & AFRICA HOSPITALS CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 MIDDLE EAST & AFRICA CLINICS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 27 MIDDLE EAST & AFRICA DIAGNOSTIC CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 MIDDLE EAST & AFRICA RADIOLOGY CENTERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 29 MIDDLE EAST & AFRICA LABORATORIES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 MIDDLE EAST & AFRICA OTHERS IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 31 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 32 MIDDLE EAST & AFRICA DIRECT TENDER IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 MIDDLE EAST & AFRICA RETAIL SALES IN HEREDITARY CANCER TESTING MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 39 MIDDLE EAST AND AFRICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 40 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 41 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 42 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 43 MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 44 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

TABLE 45 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)

TABLE 46 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)

TABLE 47 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 48 SOUTH AFRICA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 49 SOUTH AFRICA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 50 SOUTH AFRICA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 51 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 52 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 53 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 54 SOUTH AFRICA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 55 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

TABLE 56 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)

TABLE 57 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)

TABLE 58 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 59 SAUDI ARABIA BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 60 SAUDI ARABIA IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 61 SAUDI ARABIA LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 62 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 63 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 64 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 65 SAUDI ARABIA HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 66 U.A.E. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

TABLE 67 U.A.E. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)

TABLE 68 U.A.E. HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)

TABLE 69 U.A.E. HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 70 U.A.E. BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 71 U.A.E. IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 72 U.A.E. LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 73 U.A.E. HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 74 U.A.E. HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 75 U.A.E. HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 76 U.A.E. HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 77 EGYPT HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

TABLE 78 EGYPT HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)

TABLE 79 EGYPT HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)

TABLE 80 EGYPT HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 81 EGYPT BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 82 EGYPT IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 83 EGYPT LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 84 EGYPT HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 85 EGYPT HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 86 EGYPT HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 87 EGYPT HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 88 ISRAEL HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

TABLE 89 ISRAEL HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (UNITS)

TABLE 90 ISRAEL HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 ASP (USD)

TABLE 91 ISRAEL HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 92 ISRAEL BIOPSY IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 93 ISRAEL IMAGINING IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 94 ISRAEL LAB TESTS IN HEREDITARY CANCER TESTING MARKET, BY DIAGNOSIS TYPE, 2020-2029 (USD MILLION)

TABLE 95 ISRAEL HEREDITARY CANCER TESTING MARKET, BY TECHNOLOGY, 2020-2029 (USD MILLION)

TABLE 96 ISRAEL HEREDITARY CANCER TESTING MARKET, BY DISEASE TYPE, 2020-2029 (USD MILLION)

TABLE 97 ISRAEL HEREDITARY CANCER TESTING MARKET, BY END USERS, 2020-2029 (USD MILLION)

TABLE 98 ISRAEL HEREDITARY CANCER TESTING MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 99 REST OF MIDDLE EAST AND AFRICA HEREDITARY CANCER TESTING MARKET, BY TEST TYPE, 2020-2029 (USD MILLION)

Lista de figuras

FIGURE 1 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: MIDDLE EAST & AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: DBMR MARKET POSITION GRID

FIGURE 9 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: SEGMENTATION

FIGURE 11 EXPANDING REPRODUCTIVE GENETIC HEALTH SPACE IS EXPECTED TO DRIVE THE MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET IN THE FORECAST PERIOD

FIGURE 12 MULTI PANEL TEST SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET IN 2022 & 2029

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET

FIGURE 14 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, 2021

FIGURE 15 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, 2022-2029 (USD MILLION)

FIGURE 16 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, CAGR (2022-2029)

FIGURE 17 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE, LIFELINE CURVE

FIGURE 18 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, 2021

FIGURE 19 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, 2022-2029 (USD MILLION)

FIGURE 20 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, CAGR (2022-2029)

FIGURE 21 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DIAGNOSIS TYPE, LIFELINE CURVE

FIGURE 22 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, 2021

FIGURE 23 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, 2020-2029 (USD MILLION)

FIGURE 24 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, CAGR (2022-2029)

FIGURE 25 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY TECHNOLOGY, LIFELINE CURVE

FIGURE 26 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, 2021

FIGURE 27 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, 2022-2029 (USD MILLION)

FIGURE 28 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, CAGR (2022-2029)

FIGURE 29 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 30 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY END USER, 2021

FIGURE 31 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY END USER, 2020-2029 (USD MILLION)

FIGURE 32 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY END USER, CAGR (2022-2029)

FIGURE 33 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY END USER, LIFELINE CURVE

FIGURE 34 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, 2021

FIGURE 35 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

FIGURE 36 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 37 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET : BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 38 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: SNAPSHOT (2021)

FIGURE 39 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2021)

FIGURE 40 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2022 & 2029)

FIGURE 41 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY COUNTRY (2021 & 2029)

FIGURE 42 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: BY TEST TYPE (2022-2029)

FIGURE 43 MIDDLE EAST & AFRICA HEREDITARY CANCER TESTING MARKET: COMPANY SHARE 2021 (%)

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The Middle East and Africa Hereditary Cancer Testing Market are projected to grow at a CAGR of 11.2% during the forecast period by 2029.
The future market value of the Middle East and Africa Hereditary Cancer Testing Market is expected to reach USD 361.76 million by 2029.
The major players in the Middle East and Africa Hereditary Cancer Testing Market are Invitae Corporation, Illumina, Inc., Natera, Inc., CENTOGENE N.V., 4baseCare, Biocartis, Fulgent Genetics, Ambry Genetics, BioReference, PerkinElmer Inc., LifeLabs, Abbott, BIO-HELIX, Cepheid, Eurofins Scientific, among others.
The countries covered in the Middle East and Africa Hereditary Cancer Testing Market are South Africa, Saudi Arabia, UAE, Egypt, Israel, and the rest of the Middle East and Africa.